New Search

If you are not happy with the results below please do another search

59 search results for:

21

Early Diagnosis in Rare Diseases: The Power of Technology

Early Diagnosis in Rare Diseases: The Power of Technology In the complex world of rare diseases, early diagnosis is both critical and challenging. With over 7,000 known rare diseases affecting millions worldwide, the need for innovative diagnostic approaches has never been greater. At FFI Ventures, we collaborate closely with life-science industry partners to leverage cutting-edge [...]
23

FFI-Ventures partnerships: Veeva partner

FFI's partner network Partner: Veeva As a Veeva AI Partner, FFI-Ventures is at the forefront of integrating artificial intelligence with Veeva's industry-leading cloud solutions. We combine cutting-edge AI expertise with deep life sciences domain knowledge to help pharmaceutical and biotech companies accelerate product development, enhance market strategies, and optimize customer engagement. Our collaboration with Veeva [...]
24

Partners

Our Partner Network Top-Tier Partners, Tailored Solutions To address your organization’s most challenging issues, we’ve joined forces with a diverse network of top-tier partners — combining FFI’s expertise with specialized capabilities from industry leaders. Strategic AI Partner Certified Veeva AI Partner FFI-Ventures is a certified Veeva AI Partner, delivering AI-powered solutions directly integrated with the […]

25

Boost your gen AI ROI: Scaling AI projects multiplies returns

Boost Your ROI: Scaling AI Projects Multiplies Returns Successfully scaling generative AI projects can significantly boost your ROI. While initial returns from pilot projects may be limited, scaling these initiatives can yield three times the return compared to those that never move beyond the pilot stage. For every dollar invested in AI, companies see an [...]
26

ONERAY.AI Capability Update: Document Summarization & Discussion

ONERAY.AI capability update Exciting update! Our private Hashtag#generativeAI solution OneRay.AI, co-created with Pharma and Biotech partners just released a capability update. This state-of-the-art tool now offers ad-hoc summarization and discussion for up to 5 documents simultaneously in a secure, Pharma-compliant environment. It supports multiple formats, including images and graphs, and validates with Hashtag#Veeva and approved [...]
27

Competencies that drive impact in Rare Diseases

Competencies that drive impact in Rare Disease We contribute to the management of rare diseases by fostering collaboration between life-science companies, patients, and support networks at global scale. The journey to diagnose a rare disease often spans 6 to 8 years due to the complexity and rarity of these conditions, often compounded by misdiagnoses and [...]
28

FFI generative AI framework & key services

FFI generative AI framework & key services Ready to unlock the impact of #GenAI this summer? With over 18 months of diverse experience, FFI can rapidly support your organization in maximizing AI value creation. From strategy and governance to execution, we guide you through every step - including setting up your custom, private #GenerativeAI environment. [...]
29

Webinar Recording – What ROI to expect from Pharma, MedTech, BioTech generative aI projects?

Webinar Recording - What ROI to expect from Pharma, MedTech, BioTech generative aI projects? 'Maximizing ROI in Pharma: AI Use Case Prioritization' - A crucial webinar for Pharma, Biotech & Medtech budget holders. Learn to prioritize AI investments for optimal business impact, feasibility, and ROI. Watch now to inform your AI resource allocation decisions." [avia_codeblock_placeholder [...]
30

Maximizing ROI in Pharma: A Deep Dive into AI Use Case Prioritization

Maximizing ROI in Pharma: A Deep Dive into AI Use Case Prioritization The prioritization grid for generative AI use cases in the pharmaceutical industry provides a comprehensive overview of various use cases FFI-Ventures is working on today and within the last 18 months. The grid outlines the potential business impact, and technical feasibility of use [...]